Heron Therapeutics Inc
HRTX
Company Profile
Business description
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Contact
100 Regency Forect Drive
Suite 300
CaryNC27518
USAT: +1 858 251-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
122
Stocks News & Analysis
stocks
Is the relationship between risk and return broken?
Mark and Shani run through Bob Haugen’s research that explores whether lower-volatility stocks outperform higher-volatility stocks over time.
stocks
Ask the Analyst: Why are ASX gold miners overvalued despite a near record gold price?
All that glitters is not gold.
stocks
Chart of the Week: Looking past the oil shock to find consumer opportunities
Shoppers are being hit by double whammy of oil and rising rates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,009.40 | 2.70 | -0.03% |
| CAC 40 | 8,202.08 | 97.34 | -1.17% |
| DAX 40 | 24,663.61 | 255.08 | -1.02% |
| Dow JONES (US) | 49,596.97 | 313.62 | -0.63% |
| FTSE 100 | 10,276.95 | 161.71 | -1.55% |
| HKSE | 26,626.28 | 412.50 | 1.57% |
| NASDAQ | 25,806.20 | 32.75 | -0.13% |
| Nikkei 225 | 62,547.21 | 286.63 | -0.46% |
| NZX 50 Index | 13,193.23 | 77.38 | -0.58% |
| S&P 500 | 7,337.11 | 28.01 | -0.38% |
| S&P/ASX 200 | 8,776.00 | 4.80 | -0.05% |
| SSE Composite Index | 4,180.09 | 19.92 | 0.48% |